Biopharma Development & Clinical Outsourcing Business & Trends

Biopharma Vital Signs – Part 3: Pressure Points

From clinical translation and regulatory expectations to manufacturing readiness, capital constraints, and commercial viability, experts identify the pressure points shaping the path from discovery to market

07/03/2026 13 min read

Content Currently Unavailable

Cell & Gene Power List Development & Clinical

Musings from The Power List: John Maher

August 14, 2026

4 min read

John Maher discusses the scientific and practical challenges of bringing CAR T-cell therapies to patients with solid tumors

Development & Clinical Regulation & Standards Business & Trends

From Training Burden to Training Value

August 14, 2026

0 min read

Why effective study training depends on relevance, timing, and oversight.

Cell & Gene Development & Clinical Interviews

Why Cell Therapy Needs a Digital Backbone

August 13, 2026

8 min read

Alexander Seyf on why the UK is losing ground in cell and gene therapy, the real bottlenecks to commercialization, and why digitalization is no longer optional

Outsourcing Biopharma Business & Trends

Musings from The Power List: Ali Pashazadeh

August 7, 2026

7 min read

Ali Pashazadeh argues that management failures sink too many clinical programs – and explains why commercial discipline must start much earlier

Explore

Featured Topics

Issues

Topics

News & Blogs

Community & Awards

Biopharma Vital Signs – Part 3: Pressure Points

Recommended

Related Content

Musings from The Power List: John Maher

From Training Burden to Training Value

Why Cell Therapy Needs a Digital Backbone

Musings from The Power List: Ali Pashazadeh